Antengene Will Present New T Cell Engager Platform
The company will debut preclinical data on its CD2-based costimulatory platform at the 2026 SITC Annual Meeting.
Updated on Oct. 3, 2026 in Biotech
Antengene is scheduled to present preclinical results for its Cos-TCE platform at the SITC 2026 Annual Meeting in Phoenix, occurring November 4 to 8, 2026. The presentation will detail a research-stage CD2-based costimulatory T cell engager platform.
Why it matters
The platform is designed to minimize cytokine release syndrome while enhancing therapeutic efficacy, addressing a common safety hurdle in T cell engager treatments. The technology aims to improve the selectivity of immune-based cancer therapies.
The platform utilizes a 2+1 bivalent binding architecture for low-expressing targets and incorporates proprietary CD3 sequences with fast on/off kinetics. It also employs steric-hindrance-based CD3 masking to improve targeting precision.
The players
Antengene
A biopharmaceutical company headquartered in Shanghai and Hong Kong that develops hematology and oncology therapeutics with 35 investigational new drug approvals.
Dr. Bing Hou
The researcher leading the presentation of the Cos-TCE platform results at the upcoming SITC Annual Meeting.
The details
The Cos-TCE platform functions by integrating a CD3γε/δε-targeting antibody, which directs T cells to specific tumor markers. By using steric hindrance—a mechanism where the physical size of molecules blocks specific binding sites—the platform aims to prevent off-target activation. The fast on/off kinetics of the CD3 sequences are designed to modulate immune response intensity, reducing the risk of cytokine release syndrome, an inflammatory condition where immune cells are overstimulated.
Timeline
November 4 to 8, 2026: The SITC 2026 Annual Meeting takes place in Phoenix.
November 6, 2026: Dr. Bing Hou will lead the Rapid Oral Abstract Presentation regarding the Cos-TCE platform.
The Tech Race
Antengene joins a crowded field of firms competing to optimize the therapeutic index of T cell engagers. Its focus on CD2-based costimulation and CD3 masking represents a specific attempt to improve upon first-generation engager designs.
The development of the Cos-TCE platform is currently restricted to preclinical research and is not available for patient treatment. Observers should track the upcoming oral abstract presentation for evidence of safety and efficacy benchmarks.
The takeaway
The research highlights a shift toward refined antibody-based immune targeting designed to reduce systemic toxicity. Watch for the SITC abstract disclosure on November 6, 2026, to assess how the Cos-TCE mechanism compares to current standard-of-care bispecific antibodies.
What happens next
Antengene will present the Cos-TCE findings during the Rapid Oral Abstract Presentation, abstract number 15749, on November 6, 2026.
Further reading
For more on the latest advancements in cellular therapy, visit Biotech.
